Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Inventory (2018 - 2025)

Historic Inventory for Akebia Therapeutics (AKBA) over the last 8 years, with Q3 2025 value amounting to $18.6 million.

  • Akebia Therapeutics' Inventory fell 902.75% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 902.75%. This contributed to the annual value of $16.2 million for FY2024, which is 351.79% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Inventory is $18.6 million, which was down 902.75% from $16.7 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Inventory ranged from a high of $45.2 million in Q3 2022 and a low of $15.7 million during Q4 2023
  • Over the past 5 years, Akebia Therapeutics' median Inventory value was $21.6 million (recorded in 2022), while the average stood at $27.3 million.
  • Its Inventory has fluctuated over the past 5 years, first plummeted by 6376.97% in 2021, then soared by 3429.71% in 2022.
  • Akebia Therapeutics' Inventory (Quarter) stood at $36.6 million in 2021, then plummeted by 41.12% to $21.6 million in 2022, then fell by 27.25% to $15.7 million in 2023, then grew by 3.52% to $16.2 million in 2024, then increased by 14.78% to $18.6 million in 2025.
  • Its Inventory stands at $18.6 million for Q3 2025, versus $16.7 million for Q2 2025 and $19.7 million for Q1 2025.